| Kirana Narayana, MD | |
|
225 Smith Ave N, Suite 300, Saint Paul, MN 55102-2533 | |
| (612) 262-1166 | |
| Not Available |
| Full Name | Kirana Narayana |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 32 Years |
| Location | 225 Smith Ave N, Saint Paul, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073620803 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 15076R (Louisiana) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 49578 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Allina United Hospital | Saint paul, MN | Hospital |
| District One Hospital | Faribault, MN | Hospital |
| Mercy Hospital | Coon rapids, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allina Health System | 4587573613 | 3071 |
News Archive
Britain's Health Protection Agency (HPA) has published the Annual Report on Healthcare Associated Infection 2007, as well as the latest quarterly report on the MRSA blood poisoning and Clostridium difficile (C. difficile) infection figures.
University of Florida researchers will receive $250,000 to study an inventive cell-transfer therapy to treat cortical dysplasia, a condition where the brain develops abnormally before birth, causing severe epilepsy in children and adults.
A drug discovery scientist typically screens up to 10,000 compounds in the early stages of developing one FDA approved drug. During this high-throughput screening, candidate compounds are initially tested on cell and tissue samples.
A clinical study funded by the National Institutes of Health has found that young, single black women in South Africa adhered to a daily pill regimen to prevent HIV infection-an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP. This finding is the first strong indication that this population at substantial HIV risk could accept and reliably adhere to daily PrEP dosing.
Mylan Inc. today announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company for $550 million in cash. Bioniche Pharma will provide Mylan not only an immediate entry into the North American injectables market but also a platform for future growth opportunities. This transaction is expected to be accretive to Mylan's earnings in year one, without accounting for any operational or other synergies.
› Verified 2 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
Britain's Health Protection Agency (HPA) has published the Annual Report on Healthcare Associated Infection 2007, as well as the latest quarterly report on the MRSA blood poisoning and Clostridium difficile (C. difficile) infection figures.
University of Florida researchers will receive $250,000 to study an inventive cell-transfer therapy to treat cortical dysplasia, a condition where the brain develops abnormally before birth, causing severe epilepsy in children and adults.
A drug discovery scientist typically screens up to 10,000 compounds in the early stages of developing one FDA approved drug. During this high-throughput screening, candidate compounds are initially tested on cell and tissue samples.
A clinical study funded by the National Institutes of Health has found that young, single black women in South Africa adhered to a daily pill regimen to prevent HIV infection-an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP. This finding is the first strong indication that this population at substantial HIV risk could accept and reliably adhere to daily PrEP dosing.
Mylan Inc. today announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company for $550 million in cash. Bioniche Pharma will provide Mylan not only an immediate entry into the North American injectables market but also a platform for future growth opportunities. This transaction is expected to be accretive to Mylan's earnings in year one, without accounting for any operational or other synergies.
› Verified 2 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457657249 PECOS PAC ID: 4587573613 Enrollment ID: O20221213001713 |
News Archive
Britain's Health Protection Agency (HPA) has published the Annual Report on Healthcare Associated Infection 2007, as well as the latest quarterly report on the MRSA blood poisoning and Clostridium difficile (C. difficile) infection figures.
University of Florida researchers will receive $250,000 to study an inventive cell-transfer therapy to treat cortical dysplasia, a condition where the brain develops abnormally before birth, causing severe epilepsy in children and adults.
A drug discovery scientist typically screens up to 10,000 compounds in the early stages of developing one FDA approved drug. During this high-throughput screening, candidate compounds are initially tested on cell and tissue samples.
A clinical study funded by the National Institutes of Health has found that young, single black women in South Africa adhered to a daily pill regimen to prevent HIV infection-an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP. This finding is the first strong indication that this population at substantial HIV risk could accept and reliably adhere to daily PrEP dosing.
Mylan Inc. today announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company for $550 million in cash. Bioniche Pharma will provide Mylan not only an immediate entry into the North American injectables market but also a platform for future growth opportunities. This transaction is expected to be accretive to Mylan's earnings in year one, without accounting for any operational or other synergies.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kirana Narayana, MD 2950 Chicago Avenue, Minneapolis, MN 55407 Ph: (612) 262-5000 | Kirana Narayana, MD 225 Smith Ave N, Suite 300, Saint Paul, MN 55102-2533 Ph: (612) 262-1166 |
News Archive
Britain's Health Protection Agency (HPA) has published the Annual Report on Healthcare Associated Infection 2007, as well as the latest quarterly report on the MRSA blood poisoning and Clostridium difficile (C. difficile) infection figures.
University of Florida researchers will receive $250,000 to study an inventive cell-transfer therapy to treat cortical dysplasia, a condition where the brain develops abnormally before birth, causing severe epilepsy in children and adults.
A drug discovery scientist typically screens up to 10,000 compounds in the early stages of developing one FDA approved drug. During this high-throughput screening, candidate compounds are initially tested on cell and tissue samples.
A clinical study funded by the National Institutes of Health has found that young, single black women in South Africa adhered to a daily pill regimen to prevent HIV infection-an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP. This finding is the first strong indication that this population at substantial HIV risk could accept and reliably adhere to daily PrEP dosing.
Mylan Inc. today announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company for $550 million in cash. Bioniche Pharma will provide Mylan not only an immediate entry into the North American injectables market but also a platform for future growth opportunities. This transaction is expected to be accretive to Mylan's earnings in year one, without accounting for any operational or other synergies.
› Verified 2 days ago
Wojciech Kraszkiewicz, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Nicholas Charles Boysen, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Nathan M Frink, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1690 University Ave W, Suite 570, Saint Paul, MN 55104 Phone: 651-232-4800 Fax: 651-232-4899 | |
Dr. Andrew Caraganis, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 401 Phalen Blvd, Saint Paul, MN 55130 Phone: 651-254-7670 Fax: 651-254-7676 | |
Dr. Patrick George Manning, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-4887 Fax: 651-254-1603 | |
Anthony Williams, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Samantha May Scheid, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 401 Phalen Blvd, Saint Paul, MN 55130 Phone: 651-254-7980 |